Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | NAMPT | P43490 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.33 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.33 |
| ▸ | BRAF | P15056 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.32 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.32 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.32 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.32 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 2/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9939795 | 0.90 | NPC1 (0.41) | NPC1RAB9AKCNQ3KCNQ2SMN1; SMN2 | |
| SCHEMBL9939798 | 0.90 | NPC1 (0.39) | KCNH2NPC1RAB9AKCNQ3KCNQ2 | |
| SCHEMBL9939800 | 0.89 | CNR2 (0.38) | CNR2GSK3BKCNH2KCNQ3KCNQ2 | |
| SCHEMBL9939667 | 0.88 | CNR2 (0.45) | CNR2GSK3BKCNH2NAMPTMAPK1 | |
| SCHEMBL9939757 | 0.88 | KCNQ3 (0.40) | KCNH2NPC1RAB9AKCNQ3KCNQ2 | |
| SCHEMBL9939843 | 0.86 | EPHX2 (0.38) | CNR2GSK3BKCNH2NAMPTRAB9A | |
| SCHEMBL9939536 | 0.83 | KCNQ3 (0.37) | KCNH2NAMPTKCNQ3KCNQ2ACKR3 | |
| SCHEMBL9939501 | 0.79 | PDE4B (0.39) | KCNQ3KCNQ2ACKR3 | |
| SCHEMBL16621973 | 0.78 | MAPK1 (0.37) | KCNQ3KCNQ2NTRK1MAPK1ACKR3 | |
| SCHEMBL9939488 | 0.77 | RXFP1 (0.44) | CNR2NPC1RAB9ASMN1; SMN2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9370507-B2 | Pyridonyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof | LYCERA CORPORATION (US) | 2016-06-21 | — | — | US | disclosed |
| US-9370507-B2 | Pyridonyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof | LYCERA CORPORATION (US) | 2016-06-21 | — | — | US | disclosed |
| EP-2648710-B1 | PYRIDONYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | LYCERA CORP (US) | 2016-06-15 | — | — | EP | disclosed |
| US-20150335625-A1 | PYRIDONYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2015-11-26 | — | — | US | disclosed |
| US-20150335625-A1 | PYRIDONYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2015-11-26 | — | — | US | disclosed |
| US-9000014-B2 | Pyridonyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof | LYCERA CORPORATION (US) | 2015-04-07 | — | — | US | disclosed |
| US-9000014-B2 | Pyridonyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof | LYCERA CORPORATION (US) | 2015-04-07 | — | — | US | disclosed |
| WO-2012078869-A1 | PYRIDONYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | LYCERA CORPORATION (US) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150335625-A1 | PYRIDONYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | ATP5F1A, ATP5ME, ATP5F1B | CNR2 4140/4885GSK3B 4123/4885KCNH2 1659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.